Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | February 03, 2014

Nuc Med Promises HIV Cure

My generation has seen the rise of a frightening kind of STD, one that was unflinchingly lethal early on and since has been unrelenting, if survivable. Today AIDS is managed, not cured, the lethality of its cause, HIV, held at bay with a cocktail of daily medications. But now there is hope for a cure: radioimmunotherapy (RIT) promises the destruction of HIV-infected cells and the means to verify it.

Researchers at Albert Einstein College of Medicine have used RIT to kill cells infected with HIV. They were destroyed in the blood samples of patients treated with a retroviral antibody. Optimism rising from the in vitro work has been bolstered by in vivo studies on mice, according to Ekaterina (Kate) Dadachova, Ph.D., who says clinical studies are scheduled to begin soon. “Our research showed that RIT is able to kill HIV-infected cells both systemically and within the central nervous system,” said Dadachova, a professor of radiology, microbiology and immunology at Albert Einstein College of Medicine at Yeshiva University.

The experimental therapy may vanquish the HIV infection within the patient, she said, just as the radioactive element of the RIT – 213-bismuth – allows SPECT to track its march to HIV infected cells. Dadachova plans to use SPECT imaging to track the RIT in a clinical trial set to begin later this year in collaboration with the University of Pretoria in South Africa.

This shot at a cure may be coming none too soon. Increasingly virulent strains of HIV are showing up around the world. They are recombinants created when a person becomes infected with two different strains that fuse into a novel and more virulent form. Exemplifying the danger of such recombination is a form discovered and reported last year by Lund University in Sweden. Called A3/02, it is a cross between the two most common strains in Guinea-Bissau, West Africa — 02AG and A3.

This new strain has been found so far only in West Africa. But research has determined that recombinants are spreading globally at an increasing rate. Particularly susceptible are countries with high levels of immigration, such as the United States and Europe.

RIT is not a cure in itself but one that holds promise when used in concert with highly active antiretroviral therapy (HAART). Widely used to treat HIV-infected patients, HAART suppresses viral replication. But, while reducing the burden of HIV, reservoirs of latently infected cells are believed to persist in the body.

"HAART cannot kill the HIV-infected cells,” Dadachova said. RIT might.

In the research, Dadachova and her team administered RIT to blood samples from 15 HIV patients treated with HAART at the Einstein-Montefiore Center for AIDS Research. The preliminary research showed the RIT killed HIV-infected lymphocytes previously treated with HAART, reducing the HIV infection in the blood samples to undetectable levels. “The elimination of HIV-infected cells with RIT was profound and specific,” she said. “The radionuclide we used delivered radiation only to HIV-infected cells without damaging nearby cells.”

The RIT uses a type of monoclonal antibody (mAb2556) paired with bismuth radioisotope. When injected into the patient's bloodstream, the combination is expected to travel to the HIV-infected cell, which should then be destroyed by the radiation.

Raising expectations that there will be no refuge for HIV, Dadachova and her team have demonstrated that the radiolabeled antibody can cross the human blood brain barrier to reach HIV-infected cells in the brain and central nervous system. “Antiretroviral treatment only partially penetrates the blood brain barrier, which means that even if a patient is free of HIV systemically, the virus is still able to rage on in the brain, causing cognitive disorders and mental decline,” she said. “Our study showed that RIT is able to kill HIV-infected cells both systemically and within the central nervous system.”

Related Content

ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init